From: Enhancement of therapeutic potential of mesenchymal stem cell-derived extracellular vesicles
MSC origin | Model | In vivo/in vitro potency | Associated molecule | Ref. |
---|---|---|---|---|
H - AD | Angiogenesis | Increased angiogenic capacity of endothelial cells | miR-125a | [122] |
H - AD | Prostate cancer | Decreased proliferation and increased apoptosis | miR-145 | [65] |
H - BM | Optic nerve crush | Promoted regeneration of retinal ganglion cells axons | Argonaute-2 | [34] |
H - BM | Leukocyte activation (in vitro) | Decreased inflammatory cytokines in leukocytes | COX2/PGE2 | [35] |
H - BM | Nasopharyngeal carcinoma | Promoted nasopharyngeal carcinoma cell growth | FGF19 | [38] |
H - BM | Breast cancer | Inhibited endothelial cell migration and tube formation using supernatants from EV-treated breast cancer cells | miR-100 | [123] |
H - BM | Intervertebral disc degeneration | Inhibited nucleus pulposus cell apoptosis | miR-21 | [54] |
H - BM | Cardiomyocyte contractility (in vitro) | Increased contractility | miR-21p | [124] |
H - BM | Gastric cancer | Increased gastric cancer cell migration and invasion | miR-221 | [69] |
H - BM | Metastatic breast cancer | Induced dormancy | miR-23b | [125] |
H - BM | Acute myeloid leukemia | Different patterns of miRNA expression in EVs | miR-26a-5p, miR-101-3p, miR-23b-5p, miR-339-3p, miR-425-5p | [126] |
H - BM | Skeletal muscle regeneration | Increased myogenesis and angiogenesis | miR-494 | [127] |
H - BM | Acute kidney injury | Recovery from renal injury | mRNA (CCNB1, CDK8, CDC6) | [128] |
H - DP | Ischemia | Increased angiogenesis | Jagged1 | [31] |
H - EMB | Osteochondral defect | Increased cartilage repair | CD73 | [33] |
H - END | Cardiac infarction (in vitro) | Anti-apoptotic/anti-angiogenic effects and cardioprotection | miR-21 | [59] |
Human glioma | Glioma stem cell activation (in vitro) | Increased glioma stem cell tumorigenicity | miR-1587 | [129] |
H - PL | Hindlimb ischemia | Increased proangiogenic effect | VEGF/miR-126 | [92] |
H - UC | Myocardial infarction | Increased endothelial cell migration and tube formation | PDGF-D | [32] |
H - UC | Cisplatin-injured renal tubular epithelial cells (in vitro) | Protected against cisplatin-induced injury in renal tubular epithelial cells | 14-3-3ζ | [37] |
H - UC | Hypoxia-ischemia (in vitro) | Anti-apoptotic effect | miR-let-7e, miR-let-7a | [130] |
H - UC | Hepatitis (in vitro) | Protected against infection by hepatitis C virus | miR-let-7f, miR-145, miR-199a, miR-221 | [66] |
H - UC | Sepsis | Increased survival in mice and decreased inflammatory cytokines in macrophages | miR-146a | [85] |
H - UC | Skin defect | Reduced scar formation and myofibroblast development | miR-21, miR-23a, miR-125b, miR-145 | [56] |
H - UC | Skin defect in diabetes | Promoted healing of cutaneous wounds | miR-let-7b | [84] |
M - BM | Acute kidney injury | Recovery from renal injury | CCR2 | [36] |
M - BM | Kidney transplantation | Increased graft survival | miR-146a | [131] |
M - BM | Systemic sclerosis | Increased osteogenesis and decreased adipogenesis | miR-151-5p | [132] |
M - BM | Breast cancer | Decreased angiogenesis | miR-16 | [133] |
M - BM | Hematopoietic cell activation (in vitro) | Decreased autophagy and rejuvenating effects depending on age | miR-17, miR-34a (negative effect), RNA (positive effect) | [134] |
M - BM | Alzheimer’s disease | Prevented cognitive decline | miR-21 | [55] |
M - BM | Myocardial infarction | Promoted cardiac protection | miR-210 | [91] |
M - BM | Hindlimb ischemia | Restored blood perfusion and promoted angiogenesis | miR-210-3p, VEGF | [135] |
M - BM | Cardiac infarction | Decreased cardiac fibrosis | miR-22 | [136] |
M - BM | Sepsis | Recovered cardiac function | miR-223 | [137] |
M - BM | Gastric cancer | Increased proliferation and migration | UBR2 | [39] |
M - EMB | Angiogenesis | Increased angiogenic capacity of endothelial cells | miR-30b | [138] |
R - AD | Erectile dysfunction in diabetes | Restored erectile function | miR-126, miR-130a, miR-132, miR-let7b, miR-let7c | [139] |
R - BM | Renal fibrosis (in vitro) | TGF-β induced epithelial mesenchymal transition in HK2 cells | miR-294, miR-133b-3p | [140] |
R - BM | Stroke | Neuroprotective effects | miR-133b | [141] |
R - BM | Middle cerebral artery occlusion | Promoted neurite outgrowth | miR-133b | [142] |
R - BM | Colitis | Decreased colitis-associated fibrosis | miR-200b | [143] |
R - BM | Ischemic cardiomyopathy (in vitro) | Reduced oxidative injury | miR-21 | [58] |